欧洲多中心研究:射频消融治疗脊柱骨样骨瘤与骨母细胞瘤的技术成功率和长期临床结局
这项欧洲六中心研究评估了CT引导下射频消融治疗87例脊柱骨样骨瘤(77例)或骨母细胞瘤(10例)的技术成功率和长期结局,技术成功率为94.3%(82/87),临床成功率为89.7%(78/87),无重大并发症,疼痛及日常和运动活动受限的VAS评分均显著下降。
要点
- CT引导射频消融治疗脊柱骨样骨瘤/骨母细胞瘤技术成功率94.3%(82/87),临床成功率89.7%(78/87),无重大并发症。
- 87例中86例(98.9%)疼痛程度减轻,中位随访29.35±35.59个月后总体疼痛评分从8.04±0.96持续降至1.46±1.95(p<0.001)。
- 日常活动受限VAS从5.70±2.73降至0.67±1.61,运动活动受限VAS从6.40±2.58降至0.67±1.61(均p<0.001)。
核心结论
- 在多中心环境下,本试验证明射频消融是治疗脊柱骨样骨瘤/骨母细胞瘤安全有效的方法,经多学科病例讨论后应被视为一线治疗。
研究设计与样本
- 欧洲六中心研究,纳入87例脊柱骨样骨瘤(77例)或骨母细胞瘤(10例)患者,经三维CT引导入路规划后行CT引导射频消融,通过临床检查和问卷(含10点视觉 analogue 量表)评估长期结局。
关键影像表现/征象
- 病灶位于颈椎(骨样骨瘤9例/骨母细胞瘤3例)、胸椎(27例/1例)、腰椎(29例/4例)和骶椎(12例/2例)。
- 射频消融后87例中86例(98.9%)疼痛程度减轻。
诊断标准与关键数值
- 临床成功定义为VAS评分降低>30%且患者满意。
- 技术成功率为82/87(94.3%),临床成功率为78/87(89.7%)。
- 中位随访29.35±35.59个月,总体疼痛评分从8.04±0.96降至1.46±1.95(p<0.001)。
- 日常活动受限VAS从5.70±2.73降至0.67±1.61(p<0.001),运动活动受限VAS从6.40±2.58降至0.67±1.61(p<0.001)。
临床应用与阅片要点
- 作者认为,经多学科病例讨论后,射频消融应被视为脊柱骨样骨瘤/骨母细胞瘤的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate technical success and long-term outcome of CT-guided radiofrequency ablation (RFA) of spinal osteoid osteomas (OO) and osteoblastomas (OB) in six different European centres.
METHODS: Eighty-seven patients with spinal OO (77) or OB (10) were treated with CT-guided RFA, after three-dimensional CT-guided access planning. Patient's long-term outcome was assessed by clinical examination and questionnaire-based evaluation including 10-point visual analogue scales (VAS) regarding the effect of RFA on severity of pain and limitations of daily activities. Clinical success was defined as a reduction of > 30% in the VAS score and patient's satisfaction.
RESULTS: Overall, RFA was technically successful in 82/87 cases (94.3%) with no major complications; clinical success was achieved in 78/87 cases (89.7%). The OO/OB were localized in the cervical (n = 9/3), the thoracic (n = 27/1), the lumbar (n = 29/4), and the sacral spine (n = 12/2). A decrease in severity of pain after RFA was observed in 86/87 patients (98.9%) with a persistent mean reduction of overall pain score from 8.04 ± 0.96 to 1.46 ± 1.95 (p < 0.001) after a median follow-up time of 29.35 ± 35.59 months. VAS scores significantly decreased for limitations of both daily (5.70 ± 2.73 to 0.67 ± 1.61, p < 0.001) and sports activities (6.40 ± 2.58 to 0.67 ± 1.61, p < 0.001).
CONCLUSION: In a multicentric setting, this trial proves RFA to be a safe and efficient method to treat spinal OO/OB and should be regarded as first-line therapy after interdisciplinary case discussion.
引用
- Beyer T, van Rijswijk CSP, Villagrán JM, et al. European multicentre study on technical success and long-term clinical outcome of radiofrequency ablation for the treatment of spinal osteoid osteomas and osteoblastomas. Neuroradiology. 2019. PMID: 31161261. doi:10.1007/s00234-019-02226-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。